ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO600

Frequency of Adverse Events and Risk of Relapse Following SARS-CoV-2 Vaccination in Patients with Glomerular Diseases: A Multicentre Retrospective Study

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Lionaki, Sophia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
  • Pelagia, Kriki, University of Thrace, Alexandroupolis, Alexandroupolis, Greece
  • Marinaki, Smaragdi, Laiko Geniko Nosokomeio Athenon, Athens, Attica, Greece
  • Gkalitsiou, Dimitra, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece
  • Dounousi, Evangelia, Panepistemio Ioanninon, Ioannina, Epirus, Greece
  • Flouda, Sofia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
  • Liakopoulos, Vassilios, Aristoteleio Panepistemio Thessalonikes, Thessalonike, Kentrikḗ Makedonía, Greece
  • Vaios, Vasileios, Aristoteleio Panepistemio Thessalonikes, Thessalonike, Kentrikḗ Makedonía, Greece
  • Sardeli, Angeliki, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
  • Bellos, Ioannis, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • Kleinaki, Zoi, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • Panagiotis, Giannakopoulos, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece
  • Gkika, Louiza, Panepistemio Ioanninon, Ioannina, Epirus, Greece
  • Papasotiriou, Marios, Panepistemio Patron, Patra, Periféria Dhitikís Elládh, Greece
  • Venetsanopoulou, Aliki I., Panepistemio Ioanninon, Ioannina, Epirus, Greece
  • Voulgari, Paraskevi V., Panepistemio Ioanninon, Ioannina, Epirus, Greece
  • Grapsa, Eirini, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • Stylianou, Konstantinos, Panepistemiako Geniko Nosokomeio Erakleiou Iatrike Yperesia, Heraklion, Crete, Greece
  • Panagoutsos, Stylianos A., Demokriteio Panepistemio Thrakes, Komotini, Greece
  • Boletis, Ioannis, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
Background

Sars-cov2 vaccination has altered the natural course of COVID-19. We aimed to explore the frequency of adverse events of vaccination in patients with glomerular diseases (GD) including the risk of GD relapse afterwards.

Methods

Patients were included if they had biopsy-proven GD and received at least one dose of sars-cov2 vaccine. Patients who ended up in ESKD prior to vaccination or received a GD diagnosis after vaccination were excluded. We recorded demographics, histopathological diagnosis, immunosuppressive regimens, GD outcome before and after vaccination, and adverse events associated with the vaccine. Outcomes of GD included remission, relapse, treatment resistance, ESKD, and death. The rate of GD relapse post vaccination was estimated among patients who had achieved remission.

Results

315 patients with biopsy-proven GD prior to sars-cov2 vaccination were included, with a mean age of 51(36-63) years at the time of diagnostic biopsy, of whom 142(45.1%) were males. Patients received a median of 3(3-4) vaccine doses. The median time from the diagnostic kidney biopsy to the 1st vaccine dose was 48.9(19.8-106.2) months. Among 255 patients with known GD status at vaccination, 139 (44.1%) were on immunosuppressive therapy, 224(87.8%) were on remission and 31(12.2%) were still active. 66(21.0%) patients reported systemic side effects (fever, arthralgias, myalgias) and 122(38.7%) local side effects (pain, swelling, itching, edema) associated with the vaccination. Renal function and 24-hour proteinuria remained stable after vaccination. Among patients in GD remission at vaccination, 23(9.0%) experienced a relapse during a follow up time of 18.2(15.5-20.1) months. Of those, 8 (7.8%) were on immunosuppression and 15 (18.1%) were not (p=0.058). The mean time to GD relapse following vaccination was 2.5(1.2-6.4) months.

Conclusion

According to the findings from this cohort, vaccination against sars-cov2 appears safe for patients with GD, with no significant impact in renal function or the probability for relapse.

Funding

  • Government Support – Non-U.S.